ETTLINGEN, Germany – February 22, 2018 – Bruker today announced that it has acquired IRM2, a developer of high-speed infrared (IR) imaging microscopes based on quantum cascade laser (QCL) technology. Innovative, fast QCL microscopy expands Bruker’s technology portfolio and market opportunities for infrared microscopy, with applications in biological tissue analysis and materials science, and future potential in tissue diagnostics. Financial details of the transaction were not disclosed.
QCL is a novel technology in infrared and Raman microscopy, with key customers at academic and government research institutions, as well as in pharmaceutical and biotechnology companies. The IRM2 QCL platform provides direct infrared imaging with detector arrays at very high speed. A proprietary coherence reduction technique delivers unprecedented image quality, so that the composition of large sample areas can be studied much more rapidly and at high lateral resolution.
Urban Fäh, President of Bruker Optics, stated: “Novel QCL technology can offer major speed advantages for infrared and Raman microscopy of large sampling areas, with great promise for the selective screening of biological tissues. The QCL microscopy technology expands our product portfolio, and we welcome the addition of the talented IRM2 team, which provides valuable new expertise.”
Dr. Niels Kröger-Lui, founder and CEO of IRM2, commented: “The IRM2 team is proud to become part of Bruker. This is the next step in our vision of transferring the results of our academic research to industrial products that serve customers globally. We believe that Bruker provides the environment for IRM2 to integrate our know-how and technology into innovative and competitive QCL microscopy and spectroscopy solutions.”
About Bruker Corporation (NASDAQ: BRKR)
For more than 55 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, phenomics and proteomics research, microbiology and molecular pathology research.
Head of Investor Relations
T: +1 (978) 663-3660, ext. 1479
Media Contact for Bruker Optics:
Marketing Manager Bruker Optics
T: +49 (7243) 504-2652